HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

X-linked oligodontia — Clinical Guidelines

Overview

X-linked oligodontia is a condition characterized by the congenital absence of multiple teeth due to impaired dentin mineralization, often associated with X-linked hypophosphatemia (XLH) caused by mutations in the Phex gene 6.

Diagnosis

Genetic Testing: Identification of mutations in the Phex gene 6.

Clinical Examination: Presence of oligodontia and other dental abnormalities indicative of impaired mineralization 6.

Imaging: Radiographic assessment showing hypomineralized teeth and bone abnormalities 6.

Management

Phosphate Supplementation: Essential for managing underlying XLH 1 2.

Active Vitamin D Analogs: Calcitriol or calcimimetics to improve mineral homeostasis 5.

Burosumab: A recombinant fully human monoclonal antibody targeting FGF23, recommended for severe cases 1 2.

Special Populations

Pediatrics: Early intervention with phosphate and vitamin D analogs is crucial for dental development and overall growth 1.

Comorbidities: Management should consider concurrent XLH complications, integrating multidisciplinary care 1 2.

Key Recommendations

Genetic Counseling and Early Diagnosis: Essential for affected families to manage XLH and associated dental issues effectively (Evidence: Expert opinion) 6.

Phosphate and Active Vitamin D Therapy: First-line treatment for managing XLH and supporting dental mineralization (Evidence: Strong) 1 5.

Consider Burosumab for Severe Cases: For patients with inadequate response to conventional therapy, burosumab can be highly effective (Evidence: Moderate) 1 2.

References

1 Ali DS, Carpenter TO, Imel EA, Ward LM, Appelman-Dijkstra NM, Chaussain C et al.. X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism 2025. link 2 Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA et al.. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism 2025. link 3 Bhattacharya R, Daoud I, Chatterjee A, Chatterjee S, Saha NC. An integrated . Toxicology mechanisms and methods 2022. link 4 Fratz-Berilla EJ, Breydo L, Gouya L, Puy H, Uversky VN, Ferreira GC. Isoniazid inhibits human erythroid 5-aminolevulinate synthase: Molecular mechanism and tolerance study with four X-linked protoporphyria patients. Biochimica et biophysica acta. Molecular basis of disease 2017. link 5 Leifheit-Nestler M, Kucka J, Yoshizawa E, Behets G, D'Haese P, Bergen C et al.. Comparison of calcimimetic R568 and calcitriol in mineral homeostasis in the Hyp mouse, a murine homolog of X-linked hypophosphatemia. Bone 2017. link 6 Boukpessi T, Gaucher C, Léger T, Salmon B, Le Faouder J, Willig C et al.. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin. The American journal of pathology 2010. link 7 Saillour Y, Zanni G, Des Portes V, Heron D, Guibaud L, Iba-Zizen MT et al.. Mutations in the AP1S2 gene encoding the sigma 2 subunit of the adaptor protein 1 complex are associated with syndromic X-linked mental retardation with hydrocephalus and calcifications in basal ganglia. Journal of medical genetics 2007. link 8 Zenone T, Souillet G. X-linked agammaglobulinemia presenting as pseudomonas aeruginosa septicemia. Scandinavian journal of infectious diseases 1996. link 9 Wittwer B, Kircheisen R, Leutelt J, Orth U, Gal A. New X-linked mental retardation syndrome with the gene mapped tentatively in Xp22.3. American journal of medical genetics 1996. link1096-8628(19960712)64:1<42::AID-AJMG6>3.0.CO;2-T) 10 Schrander-Stumpel C, Meyer H, Merckx D, Jones M, Israel J, Sommer A et al.. The spectrum of "complicated spastic paraplegia, MASA syndrome and X-linked hydrocephalus". Contribution of DNA linkage analysis in genetic counseling of individual families. Genetic counseling (Geneva, Switzerland) 1994. link 11 Fryns JP, Vogels A, Decock P, van den Berghe H. The hand-foot-genital syndrome: on the variable expression in affected males. Clinical genetics 1993. link 12 Maciejewski A, Merriam WF. A dual function X-ray cassette holder. Injury 1984. link90018-4) 13 Wettke-Schäfer R, Kantner G. X-linked dominant inherited diseases with lethality in hemizygous males. Human genetics 1983. link

X-linked oligodontia